Press Release April 04, 2018

PDX Finder — Free global portal for cancer models

First global online catalog of Patient-Derived Xenograft models helps cancer researchers save valuable time.

Summary

  • PDX Finder is the first open and free global online catalogue for Patient-Derived Xenograft (PDX) models, which are increasingly used in cancer research
  • PDX models are some of the most effective tools for mimicking a patient’s cancer, which makes them useful for developing new cancer treatments
  • This global catalogue for PDX models will help cancer researchers coordinate efforts to understand and treat the disease more effectively

The European Bioinformatics Institute (EMBL-EBI) and The Jackson Laboratory (JAX) have jointly developed the first open cancer research portal for Patient-Derived Xenograft (PDX) models. The freely available PDX Finder is hosted by EMBL-EBI and catalogues PDX models from numerous global repositories. The PDX Finder web portal offers significant potential for collaborative research, as well as time savings for researchers, who now only have to search one central catalogue instead of going through a range of individual and distributed resources.

Clinically relevant

Researchers create PDX mouse models by implanting tumor fragments from cancer patients into mice with suppressed immune function. By using these models, researchers can get a better idea of how a specific patient would react to a specific drug.

Preclinical models such as PDX models are very important predictors of the efficacy of anticancer therapies, which currently have a high failure rate in clinical trials,” says Nathalie Conte, PDX Finder Project Lead at EMBL-EBI. “Cancer models are essential for understanding and treating cancer. PDX models are increasingly recognized as clinically relevant because they retain the patient tumor characteristics and imitate a specific patient’s response to drugs more accurately than other models. However, until now, there was no open central catalogue for PDX models. PDX Finder enables cancer researchers to search through a wider variety of models more quickly, saving valuable time and enabling collaborations.”

Centralized catalog

As the use of PDX models increases, so does the need to easily find relevant models that are distributed by different organizations around the world. PDX Finder joins together many of these individual efforts, as it builds on The Jackson Laboratory’s PDX resource which was developed in partnership with more than 20 medical centers in the United States, and EMBL-EBI’s membership of EurOPDX. This ensures that the scope and reach of PDX Finder is wider than any other individual resource available.

“Both EMBL-EBI and JAX received independent funding from the National Cancer Institute for projects that included implementation of online catalogues for PDX models,” noted Carol Bult, Scientific Director of the JAX PDX Resource. “Both groups had the goal to help basic and clinical cancer researchers find relevant models fast. With approval from the NCI, we instead collaborated to build a single, unified portal with international scope.”

The initial release of PDX Finder contains over 1900 models from multiple repositories, spanning cancers of the digestive system, respiratory tract, skin, breast, urinary system and more.

High quality models

The launch of the PDX Finder comes just months after EMBL-EBI and The Jackson Laboratory published the PDX Minimal Information standard, which sets standards for basic information needed to describe essential properties of a PDX model. The Minimal Information Standard was the result of a significant community effort that involved over 30 academic and commercial institutes around the world. The standard ensures that every model in PDX Finder is carefully described to help the researcher choose the ones that are most relevant to their work.

Researchers can search for PDX models and submit their own on the PDX Finder website: www.pdxfinder.org.

Research newsletters

Learn about the latest research breakthroughs in the fight against Alzheimer’s, cancer and other devastating diseases.